ANDA Exclusivity Protected From Patent Delisting Under Appeals Court Ruling
Generic companies will no longer lose 180-day marketing exclusivity solely because a brand name company delists a patent they have challenged
You may also be interested in...
FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.
Caraco Seeks Supreme Court Intervention In Its Prandin Patent Use Code Battle With Novo
Caraco asks the Supreme Court to decide whether it can file a counterclaim opposing Novo's revision of its patent use code for the diabetes drug.
FDA Wrangles With Generic Exclusivity, Looks To Courts For Direction
For FDA, resolving 180-day exclusivity issues may be as difficult as Lisbeth Salander’s quest to figure out Fermat’s Last Theorem.